Lecap Asset Management Ltd. Makes New $205,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)

Lecap Asset Management Ltd. bought a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 8,549 shares of the biotechnology company’s stock, valued at approximately $205,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Stifel Financial Corp lifted its position in Exelixis by 3.0% during the third quarter. Stifel Financial Corp now owns 17,330 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 506 shares during the period. Alaska Permanent Fund Corp grew its stake in shares of Exelixis by 1.5% in the 3rd quarter. Alaska Permanent Fund Corp now owns 40,855 shares of the biotechnology company’s stock worth $893,000 after buying an additional 596 shares during the last quarter. Fifth Third Bancorp increased its position in Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 604 shares in the last quarter. Panagora Asset Management Inc. raised its stake in Exelixis by 3.4% during the fourth quarter. Panagora Asset Management Inc. now owns 19,892 shares of the biotechnology company’s stock valued at $319,000 after buying an additional 662 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Exelixis by 17.1% in the third quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 668 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

NASDAQ EXEL opened at $22.70 on Tuesday. The stock has a 50 day moving average price of $22.33 and a 200-day moving average price of $22.11. Exelixis, Inc. has a one year low of $18.08 and a one year high of $24.34. The company has a market capitalization of $6.88 billion, a P/E ratio of 35.47, a P/E/G ratio of 0.60 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The company had revenue of $479.65 million for the quarter, compared to analyst estimates of $481.23 million. As a group, equities analysts predict that Exelixis, Inc. will post 1.21 EPS for the current fiscal year.

Insider Transactions at Exelixis

In related news, Director Alan M. Garber sold 19,205 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the sale, the director now owns 35,703 shares in the company, valued at $857,229.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Patrick J. Haley sold 47,020 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now directly owns 384,866 shares in the company, valued at approximately $8,255,375.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now directly owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EXEL. JMP Securities reaffirmed a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research report on Wednesday, April 10th. BTIG Research started coverage on shares of Exelixis in a report on Tuesday, December 19th. They set a “buy” rating and a $27.00 price target on the stock. William Blair restated an “outperform” rating on shares of Exelixis in a report on Friday, January 26th. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a report on Thursday, April 11th. Finally, Royal Bank of Canada boosted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $26.29.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.